NEW YORK, December 4, 2015: Morgan Lewis represented biopharmaceutical company Axsome Therapeutics (NASDAQ:AXSM) in the closing of its initial public offering of nearly 5.7 million shares of common stock at a public offering price of $9.00 per share. The IPO was closed on November 24. Axsome is a clinical stage biopharmaceutical company developing novel therapies for the management of pain and other central nervous disorders.
The Morgan Lewis team representing Axsome in this matter was led by partner Emilio Ragosa. Support was provided by partners Kathleen Sanzo and Paul Ranson, as well as associates Bryan Keighery, Oren Livne, Lisa Perri, Ryan Waggoner, Abad Mian, Jacqueline Berman, and Erin Randolph-Williams.
For further information about the offering, please see the Axsome Therapeutics press release.